procedure code and description
71250– Ct thorax w/o dye – average fee payment – $180 – $190
71275 CTA chest (noncoronary)
71260 CT thorax; with contrast (noncardiac)
71550– Mri chest w/o dye – average fee payment- $430-$440
CT Chest CPT code
PROCEDURE DESCRIPTION
• Chest 1 View 71010
• Chest 2 Views 71020
• Chest Minimum 4 Views 71030
• Chest Special Views 71035
• Ribs Unilateral 2 Views 71100
• Ribs Unilateral 2 Views with PA CXR 71101
• Ribs Bilateral 3 Views 71110
• CT chest without and with contrast 71270
• CT chest without contrast 71250
• CT chest with contrast 71260
• CT chest without contrast, high-resolution 71250
General Guidelines – Chest X-ray
A recent chest x-ray (generally within the last 60 days) that has been overread by a radiologist would be performed in many of these cases prior to considering advanced imaging.
o Identify and compare with previous chest films to determine presence and stability
o Chest x-ray can help identify previously unidentified and may direct proper advanced imaging for (2):
* pneumothorax,
* pneumomediastinum,
* fractured ribs,
* acute and chronic infections, and
* malignancies
o Exceptions to preliminary chest x-ray may include:
* Supraclavicular lymphadenopathy
* Known bronchiectasis
* Suspected interstitial lung disease
* Positive PPD or tuberculosis
* Suspected pulmonary AVM
General Guidelines –Chest CT
Intrathoracic abnormalities found on chest x-ray, fluoroscopy, abdominal CT scan, or other imaging modalities may be further evaluated with chest CT with contrast (CPT®71260).
o “Abnormalities” through these guidelines may include suspected lung or pleural nodules or masses, pleural effusion, adenopathy or other findings that are not considered benign.
Coverage Indications, Limitations, and/or Medical Necessity
A computed tomographic (CT) image is a display of the anatomy of a thin slice of the body developed from multiple x-ray absorption measurements made around the body’s periphery. Unlike conventional tomography, where the image of a thin section is created by blurring out the information from unwanted regions, the CT image is constructed mathematically using data arising only from the section of interest. Generating such an image is confined to cross sections of the anatomy that are oriented essentially perpendicular to the axial dimensions of the body. Reconstruction of the final image can be accomplished in any plane. The CT of the thorax extends from the lung apices to the posterior costophrenic sulci and may extend inferiorly to image the adrenal glands.
CT of the thorax will be considered medically reasonable and necessary based on the American College of Radiology Guidelines under the following circumstances:
· Evaluation of clinically suspected occult thoracic pathology (ACR)
· Evaluation of known or suspected thoracic vascular abnormalities (congenital or acquired)
· Evaluation and follow-up of pulmonary parenchymal and airway disease
· Assessment of cardiopulmonary failure or insufficiency
· Detection and determination of nature and extent of cardiovascular abnormalities such as but no tlimited to aneurysm, dissection, embolism, thrombosis, congenital anomalies, post-operative complications and sequelae of atherosclerotic disease
· For assessing and/or guiding drainage of pulmonary or pleural fluid collections such as abscess, empyema, effusion or pneumothorax
· For characterizing and follow-up evaluation of interstitial and alveolar lung disease due to idiopathic, allergic , collagen-vascular, environmental or other causes
· For evaluating thoracic sequelae of remote processes including but not limited to pancreatitis, gastrointestinal perforation and other processes
· For assessing injury, potential injury or thoracic sequelae after trauma, burn, surgery, transplantation, radiation therapy, chemotherapy or invasive procedure such as pacemaker placement, chest tube placement or mechanical ventilation
· Evaluation of the patient with symptoms that may be arising from the chest or be referred to the chest including but not limited to cough, hemoptysis, chest pain, abdominal pain and others
· Evaluation of abnormalities of the lungs, mediastinum, pleura and chest wall initially found on a standard chest radiographs.
· Evaluation, staging, and follow-up after therapy (e.g., surgery, radiation, and/or chemotherapy) of lung and other primary or secondary (ACR) thoracic malignancies.
· Evaluation of a patient who sustained trauma to the pleura, chest wall, mediastinum, and lung.
· Localization of a thoracic mass prior to biopsy.
· Evaluation of a patient with myasthenia gravis to rule out thymic tumors.
· CT of the Thorax is indicated for assessing the appropriateness and feasibility of percutaneous procedures such as biopsy and pleural/parenchymal drainage. CT of the thorax is also indicated for following for sequalae of, and response to treatment of these procedures. It is not expected that patients who have recently had CT scans of the thorax that documented treatable abnormalities, would undergo another CT scan of the chest at the time of the procedure. The procedure should be billed using the codes for the biopsy or drainage, with the appropriate code for CT guidance.
· Evaluation of a patient with signs and symptoms of pulmonary embolism or pulmonary emboli. (Should be performed with a multidetector spiral scanner).
· Evaluation of a patient with any other condition/symptom when there is support in medical and scientific literature for the effective use of the scan for the condition being evaluated and the scan is reasonable and necessary for the individual patient.
A CT scan is reasonable and necessary for the individual patient if the use is found to be medically appropriate considering the patient’s symptoms and preliminary diagnosis.
- Evaluation of pulmonary, mediastinal, pleural and chest wall infections and their complications.
- Detection and characterization of mediastinal neoplasms and other processes.
- Assessment of cardiopulmonary failure or insufficiency.
- Diagnosis and/or staging of neoplastic and hematologic processes arising in the thorax or with potential involvement of the thorax.
- Detection and determination of nature and extent of cardiovascular abnormalities such as, but not limited to, aneurysm, dissection, embolism, thrombosis, congenital anomalies, postoperative complications and sequelae of atherosclerotic disease.
- For assessing and/or guiding drainage of pulmonary or pleural fluid collections such as abscess, empyema, effusion or pneumothorax.
- For characterizing and follow-up evaluation of interstitial and alveolar lung disease due to idiopathic, allergic, collagen-vascular, environmental or other causes.
- For evaluating thoracic sequelae of remote processes including but not limited to pancreatitis, gastrointestinal perforation and other processes.
- For assessing injury, potential injury or thoracic sequelae after trauma, burn, surgery, transplantation, radiation therapy, chemotherapy or invasive procedure such as pacemaker placement, chest tube placement or mechanical ventilation.
- Evaluation of the patient with symptoms that may be arising from the chest or be referred to the chest, including but not limited to cough, hemoptysis, chest pain, abdominal pain and others.
- To further characterize a suspected abnormality detected by another imaging test.
To be covered under Medicare, a service shall be reasonable and necessary. When appropriate, contractors shall describe the circumstances under which the proposed LCD for the service is considered reasonable and necessary under Section 1862(a)(1)(A). Contractors shall consider a service to be reasonable and necessary if the contractor determines that the service is:
- Safe and effective.
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000, which meet the requirements of the clinical trials NCD are considered reasonable and necessary).
- Appropriate, including the duration and frequency that is considered appropriate for the service, in terms of whether it is:
- Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient’s condition or to improve the function of a malformed body member.
- Furnished in a setting appropriate to the patient’s medical needs and condition.
- Ordered and furnished by qualified personnel.
- One that meets, but does not exceed, the patient’s medical need.
- At least as beneficial as an existing and available medically appropriate alternative.
Note:
|
Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book. The American Medical Association (AMA) and the Centers for Medicare & Medicaid Services (CMS) require the use of short CPT descriptors in policies published on the Web.
|
71250©
|
Ct thorax w/o dye – Fee schedule amount – $160.46
|
71260©
|
Ct thorax w/dye Fee schedule amount – $ 224.49
|
71270©
|
Ct thorax w/o & w dye – Fee schedule amount – $
|
71275©
|
CT angiography, chest – $293.89
|
71550©
|
Mri chest w/o dye – $336.77
|
71551©
|
Mri chest w/dye $446.72
|
71552©
|
Mri chest w/o & w/dye $551.10
|
Billing and Coding Guidelines for CPT 71250 and 71260
Allowable group CPT codes – 71250 or 71260 or 71270 or 76380
Chest CT without contrast (CPT® 71250) can be used for the following:
* Patient has contraindication to contrast o Follow-up of pulmonary nodule(s)
* High Resolution CT (HRCT)
* Low-dose chest CT (CPT® 71250 or S8032) may be approved for non-Medicare lung cancer screening if all of the following criteria are met: • Patient has not received a low-dose CT lung screening in less than 12 months; and
• Patient has NO signs or symptoms suggestive of underlying lung cancer, and
• Patient is between 55 and 80 years of age; and
• Patient has at least a 30 pack-year history of cigarette smoking; and
• Currently smokes or quit less than 15 years ago
When multiple CPT submitted bundling rules applied 100% of the highest RVU, 50% of the second
This CPT required Authorization for commercial insurance
The below CPT codes are not paid seperately unless modifier applied
75571 and 76380
Chest CT with contrast (CPT 71260) is indicated in a current or past smoker with a change in cough or a new onset cough lasting greater than 4 weeks.
• Patients taking medications known to cause coughing (e.g. ACE inhibitors) should have medication discontinued. If cough persists > 4 weeks, chest CT with contrast (CPT 71260) or without contrast (CPT 71250) is indicated.
• Patients with no history of smoking and clear chest x-ray should undergo the following algorithm.1,2
o A 3 week trial of antihistamine and decongestant treatment should be performed initially.
o If chronic cough persists after treatment of upper airway cough syndrome, asthma should be ruled out with bronchoprovocation challenge (e.g. methacholine challenge, exhaled nitric oxide test) and spirometry should be performed.
o If bronchoprovocation challenge is not available, an empiric trial of corticosteroids should be performed.
o If cough persists, treatment of gastroesophageal reflux disease should be started and referral to a cough specialist is helpful.
o If cough persists, chest CT (either with contrast [CPT 71260] or without contrast [CPT 71250]) can be performed.
• Chest x-rays should be overread by a radiologist prior to request for advanced imaging.
• Intrathoracic abnormalities found on chest x-ray, fluoroscopy, abdominal CT scan, or other imaging modalities can be further evaluated with chest CT with contrast (CPT 71260).
• Non-contrast chest CT (CPT 71250) can be used for the following:
o Patient has contraindication to contrast
o Follow-up of pulmonary nodule(s)
o High Resolution CT (HRCT)
o Noncontrast CT is specifically requested by pulmonary specialist
o Other circumstances as specified in the guidelines
• Chest CT without and with contrast (CPT 71270) does not add significant diagnostic information above and beyond that provided by chest CT with contrast, unless a question regarding calcification needs to be resolved.
Chest 71275 CTA chest (noncoronary); with contrast including noncontrast images, if performed, and image post- processing
CPT Codes71250……………… Chest CT without contrast
71260……………… Chest CT with contrast
71270……………… Chest CT without contrast, followed by re-imaging with contrast
G0297 …………….. Low dose CT scan (LDCT) for lung cancer screening
Technology Considerations
* In the majority of clinical situations, chest radiographs should be performed prior to advanced imaging with CT, preferably within 30 days of the chest CT exam request.
* CT chest is not appropriate for cardiac and coronary artery imaging. Please see guidelines for cardiac CT and CCTA.
* When the purpose of the study is imaging of the heart, including the coronary arteries, do not request both a chest CT and a dedicated cardiac/coronary artery CT.
Cough persisting three (3) or more weeks with normal chest X-ray
* Unresponsive to medical treatment and/or after evaluation for other causes (e.g., post-nasal drainage, asthma, gastroesophageal reflux disease and medication effects);
OR
* Cough in immunosuppressed (e.g. HIV, after organ or bone marrow transplant, on infliximab or other tumor necrosis factor antagonists individual (In these individuals, a higher level of suspicion is warranted);
OR
* Other etiologies for chronic cough which include, but are not limited to:
* Smoking
* Chronic bronchitis
* Cough-inducing medications (e.g., ACE inhibitors)
* Exposure to an environmental irritant
* Respiratory infection
* Neoplasm
Trauma
* Injury involving the chest wall, cardiomediastinal structures and/or lungs
Bronchiectasis
* Consider high resolution chest CT (HRCT) technique
Interstitial lung disease / pulmonary fibrosis
* Consider high resolution chest CT (HRCT) technique
Pulmonary mass or suspicious parenchymal abnormality on recent chest X-ray or other imaging exam
Common Diagnostic Indications
Non-calcified nodules
* Age < 35 years:
* Nodules = 1 cm
* Nodules with suspicious morphology
* Age 35 years or older:
* Solid nodules – see Table 1
* Subsolid nodules – see Table 2
Nodules identified on incomplete thoracic CT
* Less than 6 mm – no follow-up imaging required
* 6 mm to 8 mm – 3- to 12-month follow up with complete chest CT with subsequent follow up per Table 1 or Table 2
* More than 8 mm or suspicious morphology – complete chest CT with subsequent follow up per Table 1 or Table 2
Calcified nodules
* Nodules with benign calcification patterns do not require routine follow up. This includes granulomas and nodules with popcorn calcifications.
* Follow up of nodules with other types of calcification patterns is at the discretion of the ordering provider.
Hilar enlargement on recent chest X-ray
Hoarseness, dysphonia or vocal cord weakness/paralysis
Initial evaluation when at least one of the following applies:
* Following laryngoscopy, when findings suggest recurrent laryngeal nerve dysfunction or identify a suspicious lesion
* Symptoms persisting longer than one month which are unexplained by laryngoscopy
* Presence of at least one of the following high-risk features:
* Tobacco use
* Alcohol abuse
* Hemoptysis
* History of radiation therapy
* Known head and neck malignancy
Non-acute thoracic aorta (any one of the following)
* In patients with suspected thoracic aortic aneurysm
* In patients with confirmed thoracic aortic aneurysm with new or worsening signs/symptoms
* For ongoing surveillance of stable patients with confirmed thoracic aortic aneurysm who have not undergone imaging of the thoracic aorta within the preceding six months
* In patients with confirmed aortic dissection in whom surgical repair is anticipated (to assist in preoperative planning)
* For ongoing surveillance of stable patients with confirmed aortic dissection who have not undergone imaging of the thoracic aorta within the preceding yea
r
* In patients with confirmed aortic dissection or thoracic aortic aneurysm who have undergone surgical repair within the preceding year and have not undergone imaging of the thoracic aorta within the preceding six months
* In patients being evaluated for potential transcatheter aortic valve implantation/replacement (TAVI or TAVR) provided that the patient has not undergone CTA or MRA of the chest within the preceding 60 days
Note: See acute aortic syndrome (section above) for complications of aneurysm including aortic dissection.
ICD-9-CM Codes That Support Medical Necessity
006.4
|
Amebic lung abscess
|
011.00–011.06
|
Tuberculosis of lung, infiltrative
|
011.10–011.16
|
Tuberculosis of lung, nodular
|
011.20–011.26
|
Tuberculosis of lung with cavitation
|
011.30–011.36
|
Tuberculosis of bronchus
|
011.40–011.46
|
Tuberculous fibrosis of lung
|
011.50–011.56
|
Tuberculous bronchiectasis
|
011.60–011.66
|
Tuberculous pneumonia (any form)
|
011.70–011.76
|
Tuberculous pneumothorax
|
011.80–011.86
|
Other specified pulmonary tuberculosis
|
011.90–011.96
|
Pulmonary tuberculosis, unspecified
|
012.00–012.06
|
Tuberculosis pleurisy
|
012.10–012.16
|
Tuberculosis of intrathoracic lymph nodes
|
012.20–012.26
|
Isolated tracheal or bronchial tuberculosis
|
012.30–012.36
|
Tuberculous laryngitis
|
012.80–012.86
|
Other specified respiratory tuberculosis
|
015.00–015.06
|
Tuberculosis of bones and joints, vertebral column
|
018.90
|
Miliary tuberculosis, unspecified
|
022.1
|
Pulmonary anthrax
|
022.9
|
Anthrax unspecified
|
031.0
|
Diseases due to other mycobacteria, pulmonary
|
031.8
|
Other specified mycobacterial diseases
|
038.0
|
Streptococcal septicemia
|
038.10–038.12
|
Staphylococcal septicemia
|
038.2–038.3
|
Septicemia
|
038.44
|
Septicemia due to other gram-negative organisms, serratia
|
038.49
|
Septicemia due to gram-negative organisms, other
|
038.8–038.9
|
Septicemia
|
039.1
|
Actinomycotic infections, pulmonary
|
042
|
Human Immunodeficiency Virus (HIV) disease
|
090.49
|
Juvenile neurosyphilis, other
|
093.1
|
Syphilitic aorititis
|
115.09
|
Infection by histoplasma capsulatum with other manifestation
|
117.3–117.5
|
Other mycoses
|
135
|
Sarcoidosis
|
136.3
|
Pneumocystosis
|
137.0
|
Late effects of respiratory or unspecified tuberculosis
|
140.0–140.1
|
Malignant neoplasm of lip
|
140.3–140.6
|
Malignant neoplasm of lip
|
140.8–140.9
|
Malignant neoplasm of lip
|
141.0–141.6
|
Malignant neoplasm of tongue
|
141.8–141.9
|
Malignant neoplasm of tongue
|
142.0–142.2
|
Malignant neoplasm of major salivary glands
|
142.8–142.9
|
Malignant neoplasm of major salivary glands
|
143.0–143.1
|
Malignant neoplasm of gum
|
143.8–143.9
|
Malignant neoplasm of gum
|
144.0–144.1
|
Malignant neoplasm of floor of mouth
|
144.8–144.9
|
Malignant neoplasm of floor of mouth
|
145.0–145.6
|
Malignant neoplasm of other and unspecified parts of mouth
|
145.8–145.9
|
Malignant neoplasm of other and unspecified parts of mouth
|
146.0–146.9
|
Malignant neoplasm of oropharynx
|
147.0–147.3
|
Malignant neoplasm of nasopharynx
|
147.8–147.9
|
Malignant neoplasm of nasopharynx
|
148.0–148.3
|
Malignant neoplasm of hypopharynx
|
148.8–148.9
|
Malignant neoplasm of hypopharynx
|
149.0–149.1
|
Malignant neoplasm of other and ill-defined sites within the lip, oral cavity and pharynx
|
149.8–149.9
|
Malignant neoplasm of other and ill-defined sites within the lip, oral cavity and pharynx
|
150.0–150.5
|
Malignant neoplasm of esophagus
|
150.8–150.9
|
Malignant neoplasm of esophagus
|
151.0–151.6
|
Malignant neoplasm of stomach
|
151.8–151.9
|
Malignant neoplasm of stomach
|
152.0–152.3
|
Malignant neoplasm of small intestine, including duodenum
|
152.8–152.9
|
Malignant neoplasm of small intestine, including duodenum
|
153.0–153.9
|
Malignant neoplasm of colon
|
154.0–154.3
|
Malignant neoplasm of rectum, rectosigmoid junction and anus
|
154.8
|
Malignant neoplasm of rectum, rectosigmoid junction and anus, other
|
155.0–155.2
|
Malignant neoplasm of liver and intrahepatic bile ducts
|
156.0–156.2
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
156.8–156.9
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
157.0–157.4
|
Malignant neoplasm of pancreas
|
157.8–157.9
|
Malignant neoplasm of pancreas
|
158.0
|
Malignant neoplasm of retroperitoneum
|
158.8–158.9
|
Malignant neoplasm of retroperitoneum and peritoneum
|
159.0–159.1
|
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
|
159.8–159.9
|
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
|
160.0–160.5
|
Malignant neoplasm of nasal cavities, middle ear and accessory sinuses
|
160.8–160.9
|
Malignant neoplasm of nasal cavities, middle ear and accessory sinuses
|
161.0–161.3
|
Malignant neoplasm of larynx
|
161.8–161.9
|
Malignant neoplasm of larynx
|
162.0
|
Malignant neoplasm of trachea
|
162.2–162.5
|
Malignant neoplasm of trachea, bronchus and lung
|
162.8–162.9
|
Malignant neoplasm of trachea, bronchus and lung
|
163.0–163.1
|
Malignant neoplasm of pleura
|
163.8–163.9
|
Malignant neoplasm of pleura
|
164.0–164.3
|
Malignant neoplasm of thymus, heart and mediastinum
|
164.8–164.9
|
Malignant neoplasm of thymus, heart and mediastinum
|
165.0
|
Malignant neoplasm of upper respiratory tract, part unspecified
|
165.8–165.9
|
Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs
|
170.2–170.3
|
Malignant neoplasm of bone and articular cartilage
|
171.4–171.9
|
Malignant neoplasm of connective and other soft tissue
|
172.2–172.9
|
Malignant melanoma of skin
|
173.0–173.9
|
Other malignant neoplasm of skin
|
174.0–174.6
|
Malignant neoplasm of female breast
|
174.8–174.9
|
Malignant neoplasm of female breast
|
175.0
|
Malignant neoplasm of male breast
|
175.9
|
Malignant neoplasm of male breast
|
176.4
|
Kaposi’s sarcoma
|
176.8–176.9
|
Kaposi’s sarcoma
|
179
|
Malignant neoplasm of uterus, part unspecified
|
180.0–180.1
|
Malignant neoplasm of cervix uteri
|
180.8–180.9
|
Malignant neoplasm of cervix uteri
|
181
|
Malignant neoplasm of placenta
|
182.0–182.1
|
Malignant neoplasm of body of uterus
|
182.8
|
Malignant neoplasm of other specified sites of body of uterus
|
183.0
|
Malignant neoplasm of ovary
|
183.2–183.5
|
Malignant neoplasm of ovary and other uterine adnexa
|
183.8–183.9
|
Malignant neoplasm of ovary and other uterine adnexa
|
184.8–184.9
|
Malignant neoplasm of other and unspecified female genital organs
|
185
|
Malignant neoplasm of prostate
|
186.0
|
Malignant neoplasm of undescended testis
|
186.9
|
Malignant neoplasm of testis, other and unspecified
|
187.1–187.9
|
Malignant neoplasm of penis and other male genital organs
|
188.8–188.9
|
Malignant neoplasm of bladder
|
189.0–189.4
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
189.8–189.9
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
190.0–190.9
|
Malignant neoplasm of eye
|
193
|
Malignant neoplasm of thyroid gland
|
195.0–195.5
|
Malignant neoplasm of other and ill-defined sites
|
195.8
|
Malignant neoplasm of other specified sites
|
196.0–196.3
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.5–196.6
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.8–196.9
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
197.0–197.8
|
Secondary malignant neoplasm of respiratory and digestive systems
|
198.0–198.7
|
Secondary malignant neoplasm of other specified sites
|
198.81–198.82
|
Secondary malignant neoplasm of other specified sites
|
198.89
|
Secondary malignant neoplasm of other specified sites
|
199.0–199.2
|
Malignant neoplasm without specification of site
|
200.00–200.08
|
Reticulosarcoma
|
200.10–200.18
|
Lymphosarcoma
|
200.20–200.28
|
Burkitt’s tumor or lymphoma
|
200.30–200.38
|
Marginal zone lymphoma
|
200.40–200.48
|
Mantle cell lymphoma
|
200.50–200.58
|
Primary central nervous system lymphoma
|
200.60–200.68
|
Anaplastic large cell lymphoma
|
200.70–200.78
|
Large cell lymphoma
|
200.80–200.88
|
Lymphosarcoma and reticulosarcoma, other named variants
|
201.00–201.08
|
Hodgkin’s paragranuloma
|
201.10–201.18
|
Hodgkin’s granuloma
|
201.20–201.28
|
Hodgkin’s sarcoma
|
201.40–201.48
|
Hodgkin’s disease, lymphocytic-histiocytic predominance
|
201.50–201.58
|
Hodgkin’s disease, nodular sclerosis
|
201.60–201.68
|
Hodgkin’s disease, mixed cellularity
|
201.70–201.78
|
Hodgkin’s disease, lymphocytic depletion
|
201.90–201.98
|
Hodgkin’s disease, unspecified
|
202.00–202.08
|
Nodular lymphoma
|
202.10–202.18
|
Mycosis fungoides
|
202.20–202.28
|
Sezary’s disease
|
202.30–202.38
|
Malignant histiocytosis
|
202.40–202.48
|
Leukemic reticuloendotheliosis
|
202.50–202.58
|
Letterer-Siwe disease
|
202.60–202.68
|
Malignant mast cell tumors
|
202.70–202.78
|
Peripheral T cell lymphoma
|
202.80–202.88
|
Other lymphomas
|
202.90–202.98
|
Other and unspecified malignant neoplasms of lymphoid and histocytic tissue
|
203.00–203.02
|
Multiple myeloma
|
203.10–203.12
|
Plasma cell leukemia
|
203.80–203.82
|
Other immunoproliferative neoplasms
|
204.00–204.02
|
Acute lymphoid leukemia
|
204.10–204.12
|
Chronic lymphoid leukemia
|
204.20–204.22
|
Subacute lymphoid leukemia
|
204.80–204.82
|
Other lymphoid leukemia
|
204.90–204.92
|
Unspecified lymphoid leukemia
|
205.00–205.02
|
Acute myeloid leukemia
|
205.10–205.12
|
Chronic myeloid leukemia
|
205.20–205.22
|
Subacute myeloid leukemia
|
205.30–205.32
|
Myeloid sarcoma
|
205.80–205.82
|
Other myeloid leukemia
|
205.90–205.92
|
Unspecified myeloid leukemia
|
206.00–206.02
|
Acute monocytic leukemia
|
206.10–206.12
|
Chronic monocytic leukemia
|
206.20–206.22
|
Subacute monocytic leukemia
|
206.80–206.82
|
Other monocytic leukemia
|
206.90–206.92
|
Unspecified monocytic leukemia
|
207.00–207.02
|
Acute erythremia and erythroleukemia
|
207.10–207.12
|
Chronic erythremia
|
207.20–207.22
|
Megakaryocytic leukemia
|
207.80–207.82
|
Other specified leukemia
|
208.00–208.02
|
Acute leukemia of unspecified cell type
|
208.10–208.12
|
Chronic leukemia of unspecified cell type
|
208.20–208.22
|
Subacute leukemia of unspecified cell type
|
208.80–208.82
|
Other leukemia of unspecified cell type
|
208.90–208.92
|
Unspecified leukemia of unspecified cell type
|
211.0
|
Benign neoplasm of esophagus
|
212.2–212.9
|
Benign neoplasm of respiratory and intrathoracic organs
|
213.3
|
Benign neoplasm of ribs, sternum and clavicle
|
215.4
|
Benign neoplasm of thorax
|
226
|
Benign neoplasm of thyroid glands
|
227.1
|
Benign neoplasm of parathyroid gland
|
227.6
|
Benign neoplasm of aortic body and other paraganglia
|
228.1
|
Lymphangioma any site
|
229.8
|
Benign neoplasm of other specified sites
|
230.1
|
Carcinoma in situ of esophagus
|
231.1–231.2
|
Carcinoma in situ of respiratory system
|
231.8
|
Carcinoma in situ of other specified parts of respiratory system
|
235.7–235.9
|
Neoplasm of uncertain behavior of digestive and respiratory systems
|
237.3
|
Neoplasm of uncertain behavior of paraganglia
|
237.6
|
Neoplasm of uncertain behavior of meninges
|
237.70
|
Neurofibromatosis unspecified
|
237.73
|
Schwannomatosis
|
237.79
|
Other neurofibromatosis
|
238.0–238.6
|
Neoplasm of uncertain behavior of other and unspecified sites and tissues
|
238.72–238.75
|
Neoplasm of uncertain behavior of other and unspecified sites and tissues
|
239.0–239.3
|
Neoplasm of unspecified nature
|
240.0
|
Goiter, specified as simple
|
240.9
|
Goiter, unspecified
|
241.0–241.1
|
Non-toxic nodular goiter
|
241.9
|
Non-toxic nodular goiter, unspecified
|
242.00–242.01
|
Toxic diffuse goiter
|
242.10–242.11
|
Toxic uninodular goiter
|
242.20–242.21
|
Toxic multinodular goiter
|
242.30–242.31
|
Toxic nodular goiter, unspecified
|
242.40–242.41
|
Thyrotoxicosis from ectopic thyroid nodule
|
242.80–242.81
|
Thyrotoxicosis of other specified origin
|
242.90–242.91
|
Thyrotoxicosis without mention of goiter or other cause
|
246.0–246.3
|
Other disorders of thyroid
|
246.8–246.9
|
Other disorders of thyroid
|
254.0–254.1
|
Disease of thymus gland
|
254.8–254.9
|
Disease of thymus gland
|
277.02
|
Cystic fibrosis with pulmonary manifestations
|
277.09
|
Cystic fibrosis with other manifestations
|
277.30
|
Amyloidosis, unspecified
|
277.39
|
Other amyloidosis
|
282.60
|
Sickle-cell disease unspecified
|
282.62
|
Hb-ss disease with crisis
|
282.64
|
Sickle-cell/hb c disease with crisis
|
324.0–324.1
|
Intracranial and intraspinal abscess
|
353.0
|
Brachial plexus lesions
|
358.00–358.01
|
Myasthenia gravis
|
358.1–358.2
|
Myoneural disorders
|
358.8–358.9
|
Myoneural disorders
|
391.0–391.2
|
Rheumatic fever with heart involvement
|
393
|
Chronic rheumatic pericarditis
|
398.0
|
Rheumatic myocarditis
|
415.11–415.12
|
Acute pulmonary heart disease
|
415.19
|
Other pulmonary embolism and infarction
|
416.0–416.2
|
Chronic pulmonary heart disease
|
416.8-416.9
|
Chronic pulmonary heart disease
|
417.0–417.1
|
Other diseases of pulmonary circulation
|
417.8–417.9
|
Other diseases of pulmonary circulation
|
420.0
|
Acute pericarditis in diseases classified elsewhere
|
420.90
|
Acute pericarditis unspecified
|
422.0
|
Acute myocarditis in diseases classified elsewhere
|
422.90
|
Acute myocarditis unspecified
|
423.0
|
Hemopericardium
|
423.2–423.3
|
Other diseases of pericardium
|
423.8–423.9
|
Other diseases of pericardium
|
425.1
|
Hypertrophic obstructive cardiomyopathy
|
425.4
|
Other primary cardiomyopathies
|
425.8
|
Cardiomyopathy in other diseases classified elsewhere
|
427.5
|
Cardiac arrest
|
428.0–428.1
|
Heart failure
|
428.20–428.23
|
Systolic heart failure
|
428.30–428.33
|
Diastolic heart failure
|
428.40–428.43
|
Combined systolic and diastolic heart failure
|
428.9
|
Heart failure, unspecified
|
435.2
|
Subclavian steal syndrome
|
440.0
|
Atherosclerosis of aorta
|
441.00–441.03
|
Dissection of aorta
|
441.1–441.7
|
Aortic aneurysm and dissection
|
441.9
|
Aortic aneurysm, of unspecified site without mention of rupture
|
442.82
|
Aneurysm, subclavian artery
|
442.89
|
Aneurysm, other artery
|
444.1
|
Embolism and thrombosis of thoracic aorta
|
446.20
|
Hypersensitivity angititis, unspecified
|
446.4
|
Wegener’s granulomatosis
|
447.1–447.2
|
Other disorders of arteries and arterioles
|
447.70–447.72
|
Other disorders of arteries and arterioles
|
452
|
Portal vein thrombosis
|
453.0
|
Budd-Chiari syndrome
|
453.2
|
Embolism and thrombosis of inferior vena cava
|
453.77
|
Chronic venous embolism and thrombosis of other thoracic veins
|
453.87
|
Acute venous embolism and thrombosis of other thoracic veins
|
456.0-456.1
|
Varicose veins of other sites
|
459.2
|
Compressions of vein
|
478.31
|
Unilateral partial paralysis of the vocal chords
|
480.0–480.3
|
Viral pneumonia
|
480.8–480.9
|
Viral pneumonia
|
481
|
Pneumococcal pneumonia
|
482.0–482.2
|
Other bacterial pneumonia
|
482.30–482.32
|
Pneumonia due to streptococcus
|
482.39
|
Pneumonia due to streptococcus, other
|
482.40–482.42
|
Pneumonia due to staphylococcus
|
482.49
|
Other staphylococcus pneumonia
|
482.81–482.84
|
Pneumonia due to other specified bacteria
|
482.89
|
Pneumonia, other specified bacteria
|
482.9
|
Bacterial pneumonia, unspecified
|
483.0–483.1
|
Pneumonia due to other specified organism
|
483.8
|
Pneumonia due to other specified organism
|
484.1
|
Pneumonia in cytomegalic inclusion disease
|
484.3
|
Pneumonia in whooping cough
|
484.5–484.8
|
Pneumonia in infectious diseases classified elsewhere
|
485
|
Bronchopneumonia, organism unspecified
|
486
|
Pneumonia, organism unspecified
|
487.0–487.1
|
Influenza
|
487.8
|
Influenza with other manifestations
|
490
|
Bronchitis, not specified as acute or chronic
|
491.1
|
Mucopurulent chronic bronchitis
|
491.21
|
Obstructive chronic bronchitis with (acute) exacerbation
|
491.8
|
Other chronic bronchitis
|
492.0
|
Emphysematous bleb
|
492.8
|
Other emphysema
|
494.0–494.1
|
Bronchiectasis
|
495.0–495.9
|
Extrinsic allergic alveolitis
|
496
|
Chronic airway obstruction, not elsewhere classified
|
500
|
Coal workers’ pneumoconiosis
|
501
|
Asbestosis
|
502
|
Pneumoconiosis due to other silica or silicates
|
503
|
Pneumoconiosis due to other inorganic dust
|
504
|
Pneumonopathy due to inhalation of other dust
|
505
|
Pneumoconiosis, unspecified
|
506.0–506.4
|
Respiratory conditions due to chemical fumes and vapors
|
506.9
|
Unspecified respiratory conditions due to chemical fumes and vapors
|
507.0–507.1
|
Pneumonitis due to solids and liquids
|
507.8
|
Pneumonitis due to other solids and liquids
|
508.0–508.1
|
Respiratory conditions due to other and unspecified external agent
|
508.8–508.9
|
Respiratory conditions due to other and unspecified external agent
|
510.0
|
Empyema with fistula
|
510.9
|
Empyema without mention of fistula
|
511.0–511.1
|
Pleurisy
|
511.81
|
Malignant pleural effusion
|
511.89
|
Other specified forms of effusion, except tuberculous
|
511.9
|
Unspecified pleural effusion
|
512.0–512.1
|
Pneumothorax
|
512.8
|
Other spontaneous pneumothorax
|
513.0–513.1
|
Abscess of lung and mediastinum
|
514
|
Pulmonary congestion and hypostasis
|
515
|
Post-inflammatory pulmonary fibrosis
|
516.0–516.3
|
Other alveolar and pariteoalveolor pneumonopathy
|
516.8–516.9
|
Other alveolar and pariteoalveolor pneumonopathy
|
517.1–517.3
|
Lung involvement in conditions classified elsewhere
|
517.8
|
Lung involvement in other diseases classified elsewhere
|
518.0–518.7
|
Other diseases of lung
|
518.81–518.84
|
Other diseases of lung
|
518.89
|
Other diseases of lung, not elsewhere classified
|
519.11
|
Acute bronchospasm
|
519.19
|
Other diseases of trachea and bronchus
|
519.2
|
Mediastinitis
|
530.0
|
Achalasia and cardiospasm
|
530.20–530.21
|
Ulcer of esophagus
|
530.3–530.7
|
Diseases of esophagus
|
530.84
|
Tracheoesophageal fistula
|
551.3
|
Diaphragmatic hernia with gangrene
|
552.3
|
Diaphragmatic hernia with obstruction
|
553.3
|
Diaphragmatic hernia without obstruction or gangrene
|
567.1
|
Pneumococcal peritonitis
|
567.21–567.23
|
Other suppurative peritonitis
|
567.29
|
Other suppurative peritonitis
|
567.81
|
Choleperitonitis
|
567.9
|
Unspecified peritonitis
|
577.0–577.2
|
Diseases of pancreas
|
577.8–577.9
|
Diseases of pancreas
|
610.0–610.4
|
Benign mammary dysplasias
|
610.8–610.9
|
Benign mammary dysplasias
|
611.0
|
Inflammatory disease of breast
|
611.3
|
Fat necrosis of breast
|
611.5–611.6
|
Other disorders of breast
|
611.71–611.72
|
Other disorders of breast
|
611.79
|
Other disorders of breast
|
710.0–710.1
|
Diffuse diseases of connective tissue
|
714.81
|
Rheumatoid lung
|
746.89
|
Other specified anomalies of heart
|
746.9
|
Unspecified anomaly of heart
|
747.0
|
Patent ductus arteriosus
|
747.10–747.11
|
Coarctation of aorta
|
747.20–747.22
|
Other anomalies of aorta
|
747.29
|
Other anomalies of aorta
|
747.3
|
Congenital anomalies of pulmonary artery
|
747.40–747.42
|
Anomalies of great veins
|
747.49
|
Other anomalies of great veins
|
748.3–748.5
|
Congenital anomalies of respiratory system
|
748.60–748.61
|
Other anomalies of lung
|
748.9
|
Unspecified congenital anomaly of respiratory system
|
750.3–750.4
|
Other congenital anomalies of upper alimentary tract
|
754.2
|
Certain congenital musculoskeletal deformities of spine
|
754.81–754.82
|
Other specified non-teratogenic anomalies
|
756.6
|
Congenital anomalies of diaphragm
|
759.82
|
Marfan syndrome
|
770.7
|
Chronic respiratory disease arising in the perinatal period
|
770.87–770.88
|
Other respiratory problems after birth
|
784.40–784.41
|
Voice disturbance
|
784.49
|
Other voice and resonance disorders
|
785.0–785.4
|
Symptoms involving cardiovascular system
|
785.50–785.52
|
Shock without mention of trauma
|
785.6
|
Enlargement of lymph nodes
|
786.00–786.07
|
Dyspnea and respiratory abnormalities
|
786.09
|
Other dyspnea and respiratory abnormalities
|
786.1
|
Stridor
|
786.2
|
Cough
|
786.30
|
Hemoptysis, unspecified
|
786.39
|
Other hemoptysis
|
786.4
|
Abnormal sputum
|
786.50–786.52
|
Chest pain
|
786.59
|
Chest pain, other
|
786.6–786.9
|
Symptoms involving respiratory system and other chest symptoms
|
789.00–789.07
|
Abdominal pain
|
789.1–789.2
|
Other symptoms involving abdomen and pelvis
|
789.30–789.37
|
Abdominal or pelvic swelling, mass or lump
|
789.39
|
Abdominal or pelvic swelling, mass or lump, other specified site
|
789.51
|
Malignant ascites
|
789.59
|
Other ascites
|
793.1–793.2
|
Non-specific abnormal findings on radiological and other examination of body structure
|
793.91
|
Image test inconclusive due to excess body fat
|
793.99
|
Other non-specific (abnormal) findings on radiological and other examination of body structure
|
794.2
|
Non-specific abnormal results of function study of pulmonary system
|
794.30
|
Unspecified abnormal function study of cardiovascular system
|
807.00–807.09
|
Fracture of rib(s), closed
|
807.10–807.19
|
Fracture of rib(s), open
|
807.2–807.6
|
Fracture of rib(s), sternum, larynx and trachea
|
819.0–819.1
|
Multiple closed fractures involving both upper limbs and upper limb with rib(s) and sternum
|
860.0–860.5
|
Traumatic pneumothorax and hemothorax
|
861.00–861.03
|
Injury to heart without mention of open wound into thorax
|
861.10–861.13
|
Injury to heart with open wound into thorax
|
861.20–861.22
|
Injury to lung without mention of open wound into thorax
|
861.30–861.32
|
Injury to lung with open wound into thorax
|
862.0–862.1
|
Injury to other and unspecified intrathoracic organs
|
862.21–862.22
|
Injury to other and specified intrathoracic organs, without mention of open wound into cavity
|
862.29
|
Injury to other and specified intrathoracic organs, without mention of open wound into cavity, other
|
862.31–862.32
|
Injury to other and specified intrathoracic organs, with open wound in cavity
|
862.39
|
Injury to other and specified intrathoracic organs, with open wound in cavity, other
|
862.8–862.9
|
Injury to other and unspecified intrathoracic organs
|
875.0–875.1
|
Open wound of chest (wall)
|
879.6–879.7
|
Open wound of other and unspecified parts of trunk
|
901.0–901.3
|
Injury to blood vessels of thorax
|
901.40–901.42
|
Injury to pulmonary vessel(s)
|
901.81
|
Injury to intercostal artery or vein
|
901.89
|
Injury to other specified blood vessels of thorax
|
901.9
|
Injury to unspecified blood vessel of thorax
|
906.0
|
Late effect of open wound of head neck and trunk
|
908.0
|
Late effect of internal injury to chest
|
908.4
|
Late effect of injury to blood vessel of thorax, abdomen and pelvis
|
922.1
|
Contusion of chest wall
|
926.8
|
Crushing injury of multiple sites of trunk
|
934.0–934.1
|
Foreign body in trachea, bronchus and lung
|
934.8–934.9
|
Foreign body in trachea, bronchus and lung
|
958.0–958.1
|
Certain early complications of trauma
|
958.3–958.4
|
Certain early complications of trauma
|
958.7
|
Traumatic subcutaneous emphysema
|
959.11
|
Other injury of chest wall
|
996.00
|
Mechanical complications of unspecified cardiac device implant and graft
|
996.83–996.84
|
Complications of transplanted organ
|
V10.00
|
Personal history of malignant neoplasm of unspecified site in gastrointestinal tract
|
V10.03–V10.05
|
Personal history of malignant neoplasm
|
V10.11–V10.12
|
Personal history of malignant neoplasm of trachea, bronchus and lung
|
V10.20–V10.21
|
Personal history of malignant neoplasm of other respiratory and intrathoracic organs
|
V10.29
|
Personal history of malignant neoplasm of other respiratory and intrathoracic organs
|
V10.3
|
Personal history of malignant neoplasm of breast
|
V10.40
|
Personal history of malignant neoplasm of unspecified female genital organ
|
V10.45
|
Personal history of malignant neoplasm of unspecified male genital organ
|
V10.52
|
Personal history of malignant neoplasm of kidney
|
V10.71–V10.72
|
Personal history of other lymphatic and hematopoietic neoplasms
|
V10.79
|
Personal history of other lymphatic and hematopoietic neoplasms
|
V18.19
|
Family history of other endocrine and metabolic diseases
|
V67.00
|
Follow-up examination following unspecified surgery
|
V67.09
|
Follow-up examination following other surgery
|
V67.1–V67.2
|
Follow-up examination
|
V71.1
|
Observation for suspected malignant neoplasm
|
V71.82–V71.83
|
Observation/evaluation, other specified suspected conditions
|
V71.89
|
Observation/evaluation, other specified suspected conditions
|